Group Exercise in Cancer Patients Under Active Treatment: Feasibility Pilot Study.
NCT ID: NCT06825429
Last Updated: 2025-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
50 participants
INTERVENTIONAL
2025-03-31
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial: Effectiveness and Efficiency of Physical Exercise in Cancer Patients
NCT01786122
"CHOiCE"! Choose Health: Oncological Patients Cenetered Exercise
NCT04226508
Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program
NCT03865875
Effectiveness of an Aerobic Exercise Program in Cancer Survivors.
NCT06254989
Effect of an Early Mobilization Program on Outcomes After Major Cancer Surgery
NCT01693172
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Each 45-minute session includes an initial relaxation/stretching phase, simple aerobic exercises, muscle strengthening exercises, balance exercises, and will be led by a physiotherapist. The exercises proposed to the group with ECOG 2 will be less intense and of less difficulty with the aim of adapting the activity to patients with a lower performance status (see appendix 4.5, V2, 07/10/2024). The groups will consist of a minimum of five patients and a maximum of ten. Patients will also be stimulated to perform physical activity at home to a total of 150 minutes per week. Patients will be assessed at baseline (T0), at the end of the intervention (T1,12 weeks) and 6 months after the start of the intervention (T2).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ECOG 0-1
Each 45-minute session includes an initial relaxation/stretching phase, simple aerobic exercises, muscle strengthening exercises, balance exercises and will be led by a physiotherapist
exercise programme for group with ECOG 0-1
exercise programme for group with ECOG 2
ECOG 2
The exercises proposed to the group with ECOG 2 will be less intense and less difficult with the aim of adapting the activity to patients with a lower performance status
exercise programme for ECOG 2 group
this intervention shall be proportionated to the ECOG status of the group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
exercise programme for group with ECOG 0-1
exercise programme for group with ECOG 2
exercise programme for ECOG 2 group
this intervention shall be proportionated to the ECOG status of the group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age\>= 18
* prognosis\> 12 months
* ECOG \<=2
* Walking with/ without aids
* clinically stable
* signed informed consent
* Patients with bone metastases with ECOG from 0-1 suitable results
Exclusion Criteria
* cognitive impairment that compromises collaboration and questionnaire filling
* patients with pathologies (e.g. neurological, psychiatric) that do not allow the obtaining of valid informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Besa Kopliku, MD
Role: PRINCIPAL_INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EFG 21/22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.